Olmutinib (BI1482694/HM61713), a Novel Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor, Reverses ABCG2-Mediated Multidrug Resistance in Cancer Cells-Reference-Cited by-同舟云学术

Olmutinib (BI1482694/HM61713), a Novel Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor, Reverses ABCG2-Mediated Multidrug Resistance in Cancer Cells

Published:2018-10-09 Issue: Volume:9 Page:
ISSN:1663-9812
Container-title:Frontiers in Pharmacology
language:
Short-container-title:Front. Pharmacol.

Author:

Zhang Wei,Fan Ying-Fang,Cai Chao-Yun,Wang Jing-Quan,Teng Qiu-Xu,Lei Zi-Ning,Zeng Leli,Gupta Pranav,Chen Zhe-Sheng

Funder

Foundation for the National Institutes of Health

Publisher

Frontiers Media SA

Subject

Pharmacology (medical),Pharmacology

Reference47 articles.

1. Tyrosine kinase inhibitors as reversal agents for ABC transporter mediated drug resistance.;Anreddy;Molecules,2014

2. Reversing effect of agosterol A, a spongean sterol acetate, on multidrug resistance in human carcinoma cells.;Aoki;Jpn. J. Cancer. Res.,2001

3. Overcoming ABC transporter-mediated multidrug resistance: the dual role of tyrosine kinase inhibitors as multitargeting agents.;Beretta;Eur. J. Med. Chem.,2017

4. Do cMOAT (MRP2), other MRP homologues, and LRP play a role in MDR?;Borst;Semin. Cancer Biol.,1997

5. Impact of ABCG2 polymorphisms on the clinical outcome of TKIs therapy in Chinese advanced non-small-cell lung cancer patients.;Chen;Cancer Cell Int.,2015

Cited by 50 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Olmutinib Reverses Thioacetamide-Induced Cell Cycle Gene Alterations in Mice Liver and Kidney Tissues, While Wheat Germ Treatment Exhibits Limited Efficacy at Gene Level;Medicina;2024-04-16

2. Foretinib, a c-MET receptor tyrosine kinase inhibitor, tackles multidrug resistance in cancer cells by inhibiting ABCB1 and ABCG2 transporters;Toxicology and Applied Pharmacology;2024-03

3. Design, synthesis, and biological evaluation of novel quinoxaline aryl ethers as anticancer agents;Chemical Biology & Drug Design;2024-03

4. Targeting the EGFR/RAS/RAF signaling pathway in anticancer research: a recent update on inhibitor design and clinical trials (2020–2023);Expert Opinion on Therapeutic Patents;2024-02

5. Perspectives on drug repurposing to overcome cancer multidrug resistance mediated by ABCB1 and ABCG2;Drug Resistance Updates;2023-11